经外泌体释放的高迁移率族蛋白B1在菌群紊乱非酒精性脂肪性肝病小鼠中的表达及Toll样受体4信号的调控作用
Expression of high-mobility group B1 released by exosome in nonalcoholic fatty liver disorder and regulated by TLR4 signal
- 解放军医学杂志 2023年48卷第11期 页码：1314-1320
- 作者机构：
1.西安交通大学医学院第一附属医院消化内科，陕西西安 710061
- 作者简介：
孙焕焕，医学博士，助理研究员，主要从事非酒精性脂肪性肝病等的基础及临床研究
和水祥，E-mail：dyyyjxk@mail.xjtu.edu.cn
- 基金信息：陕西省重点研发计划(2019SF-171;2018SF-051)
DOI：10.11855/j.issn.0577-7402.2484.2023.0804
中图分类号：
扫 描 看 全 文
孙焕焕, 李培杰, 冯云, 等. 经外泌体释放的高迁移率族蛋白B1在菌群紊乱非酒精性脂肪性肝病小鼠中的表达及Toll样受体4信号的调控作用[J]. 解放军医学杂志, 2023, 48(11): 1314-1320.
Sun Huan-Huan,Li Pei-Jie,Feng Yun,et al.Expression of high-mobility group B1 released by exosome in nonalcoholic fatty liver disorder and regulated by TLR4 signal[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1314-1320.
孙焕焕, 李培杰, 冯云, 等. 经外泌体释放的高迁移率族蛋白B1在菌群紊乱非酒精性脂肪性肝病小鼠中的表达及Toll样受体4信号的调控作用[J]. 解放军医学杂志, 2023, 48(11): 1314-1320. DOI： 10.11855/j.issn.0577-7402.2484.2023.0804.
Sun Huan-Huan,Li Pei-Jie,Feng Yun,et al.Expression of high-mobility group B1 released by exosome in nonalcoholic fatty liver disorder and regulated by TLR4 signal[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1314-1320. DOI： 10.11855/j.issn.0577-7402.2484.2023.0804.
摘要
目的,2,探讨非酒精性脂肪性肝病(NAFLD)小鼠中肠源性及肝源性高迁移率族蛋白B1(HMGB1)经外泌体的释放情况及其调控途径。,方法,2,15只雄性8周龄野生型C57BL/6J小鼠及10只合并肠道菌群紊乱的NAFLD小鼠(ASC,-/-,)模型。10只野生型小鼠喂食正常饲料(ND)为正常对照组、喂养高脂饮食(HFD)为高脂饮食组，每组5只，另外5只用于了解造模情况。10只ASC,-/-,小鼠分别 喂养ND(菌群紊乱组)及HFD(高脂菌群紊乱组)，每组5只。共喂养8周。采用共聚焦显微镜检测肝脏及肠黏膜外泌体标志物与HMGB1共定位情况；采用Western blotting及PCR等方法检测外泌体中HMGB1含量。通过棕榈酸(PA)及脂多糖(LPS)处理AML12细胞24 h构建体外模型，采用Western blotting检测HMGB1/CD63水平，并通过siRNA干预探讨经外泌体释放的调控机制。,结果,2,高脂饮食组的外泌体分泌较正常对照组增多[(3.5±0.2) ng/ml, vs. ,(1.1±0.3) ng/ml，,P,<,0.05]，高脂菌群紊乱组的外泌体亦高于菌群紊乱组[(3.2±0.2)ng/ml, vs. ,(1.9±0.4) ng/ml，,P,<,0.05]。免疫荧光检测结果显示，体内实验高脂饮食组与正常对照组比较，体外实验高脂内毒素组与空白对照组比较，外泌体标记物(ALP或VPS16)与HMGB1的共定位增加。PCR检测发现，高脂饮食组肝细胞外泌体中的,HMGB1,较正常对照组升高(41.5±10.2, vs. ,1.3±0.3，,P,<,0.05)，高脂菌群紊乱组较菌群紊乱组升高(48.6±7.2, vs. ,1.5±0.5，,P,<,0.05)；高脂饮食组,TLR4,较正常对照组升高(13.8±6.2, vs. ,2.8±0.9，,P,<,0.05)，高脂菌群紊乱组较菌群紊乱组升高(22.6±4.1, vs. ,2.5±1.5，,P,<,0.05)。在肠黏膜细胞中，高脂饮食组较正常对照组(0.6±0.2, vs. ,0.4±0.1，,P,<,0.05)及高脂菌群紊乱组较菌群紊乱组(0.9±0.2, vs. ,0.5±0.1，,P,<,0.05)中HMGB1与外泌体标记物(CD63)共显影增加。在体外实验中，内毒素组、高脂内毒素组外泌体的HMGB1(5.1±0.8，5.5±0.7)均较空白对照组(3.8±0.6)增加(,P,<,0.05)，而siRNA干预组与空白对照组比较无明显差异(3.7±0.6 ,vs,. 3.8±0.6，,P,>,0.05)。,结论,2,在高脂饮食及肠道菌群紊乱环境下，HMGB1在肝细胞及肠细胞中经外泌体释放，并受TLR4调控，可能是促进脂肪性肝炎发展的因素之一。
Abstract
Objective,2,To investigate the release of enterogenic and hepatogenic high mobility group protein B1 (HMGB1) through exosomes and its regulatory pathway.,Methods,2,We used wild-type (WT) and ASC,-/-, mice for this study. We randomly selected five mice per group from each strain and fed them either a normal diet (ND) or a high-fat diet (HFD) for eight weeks. The control group consisted of WT mice fed with the normal diet; the HFD group were WT mice with the HFD; the microflora disturbance (MD) group were ASC,-/-, mice fed with the normal diet; the high-lipid microflora disturbance (HLMD) group were ASC,-/-, mice with HFD. We used confocal microscopy to detect the co-localization of liver and intestinal exosome markers with HMGB1. We then measured the expression level of HMGB1 content in exosomes by Western blotting and PCR. The AML12 cells were treated with palmitic acid (PA) and lipopolysaccharide (LPS) for 24 h to build an ,in vitro, model. We also detected HMGB1/CD63 levels using Western blotting. To understand the regulatory mechanism of exosome release, we employed siRNA intervention.,Results,2,The secretion of exosomes increased significantly in HFD group compared with control group [(3.5±0.2) ng/ml, vs. ,(1.1±0.3) ng/ml,P,<,0.05], HLMD group compared with those in MD group [(3.2±0.2) ng/ml, vs. ,(1.9±0.4) ng/ml, P,<,0.05]. Using immunofluorescence detection, we observed increased co-localization of exosome markers (ALP or VPS16) with HMGB1 in HFD group compared with control group. We also observed this in AML12 cells treated with PA and LPS compared with blank control. The PCR data showed that HMGB1 in hepatocyte exosomes was higher in HFD group compared with control group (41.5±10.2, vs. ,1.3±0.3,P,<,0.05), HLMD group was significantly higher than that in MD group (48.6±7.2, vs. ,1.5±0.5,P,<,0.05). TLR4 expression was higher in HFD group compared with control group (13.8±6.2, vs. ,2.8±0.9,P,<,0.05), HLMD group compared with MD group (22.6±4.1, vs. ,2.5±1.5,P,<,0.05). In intestinal mucosal cells, the co-location of HMGB1 and exosome marker CD63 was significantly higher in HFD group compared with control group (0.6±0.2, vs. ,0.4±0.1,P,<,0.05), and HLMD group compared with MD group (0.9±0.2, vs. ,0.5±0.1,P,<,0.05)., In vitro, the HMGB1 of exosomes was increased in endotoxin group (5.1±0.8) and high lipid endotoxin group (5.5±0.7) compared with control group (3.8±0.6,P,<,0.05). On the other hand, the HMGB1 of exosomes in the cell siRNA intervention group was not increased compared with control group (3.7±0.6, vs. ,3.8±0.6,P>,0.05).,Conclusion,2,HMGB1 is released by exosomes in hepatocytes and intestinal cells, and regulated by Toll-like receptor 4 (TLR4) under a high-fat diet and intestinal flora disorder, which may be one of the contributing factors in promoting the development of steatohepatitis.
关键词
非酒精性脂肪性肝病脂肪性肝炎高迁移率族蛋白B1外泌体Toll样受体4
Keywords
nonalcoholic fatty liver diseasesteatohepatitishigh mobility group protein B1exosomeToll-like receptor 4
references
Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682.
Wesolowski SR, Kasmi KC, Jonscher KR, et al. Developmental origins of NAFLD: a womb with a clue[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(2): 81-96.
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048.
Kjærgaard K, Mikkelsen ACD, Wernberg CW, et al. Cognitive dysfunction in non-alcoholic fatty liver disease-current knowledge, mechanisms and perspectives[J]. J Clin Med, 2021, 10(4): 673.
Arriazu E, Ge XD, Leung TM, et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury[J]. Gut, 2017, 66(6): 1123-1137.
Sheller-Miller S, Radnaa E, Arita Y, et al. Environmental pollutant induced cellular injury is reflected in exosomes from placental explants[J]. Placenta, 2020, 89: 42-49.
Yao JM, Ying HZ, Zhang HH, et al. Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells[J]. Free Radic Biol Med, 2023, 195: 58-73.
Wei XL, Zheng WJ, Tian PK, et al. Administration of glycyrrhetinic acid reinforces therapeutic effects of mesenchymal stem cell-derived exosome against acute liver ischemia-reperfusion injury[J]. J Cell Mol Med, 2020, 24(19): 11211-11220.
Ye LS, Zhang Q, Cheng YS, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion[J]. J Immunother Cancer, 2018, 6(1): 145.
Li WB, Deng MH, Loughran PA, et al. LPS induces active HMGB1 release from hepatocytes into exosomes through the coordinated activities of TLR4 and caspase-11/GSDMD signaling[J]. Front Immunol, 2020, 11: 229.
Chen Y, Sun HH, Bai Y, et al. Gut dysbiosis-derived exosomes trigger hepatic steatosis by transiting HMGB1 from intestinal to liver in mice[J]. Biochem Biophys Res Commun, 2019, 509(3): 767-772.
Hou X, Yin S, Ren RX, et al. Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis[J]. Hepatology, 2021, 74(1): 116-132.
Ma C, Wang C, Zhang YF, et al. Potential natural compounds for the prevention and treatment of nonalcoholic fatty liver disease: a review on molecular mechanisms[J]. Curr Mol Pharmacol, 2022, 15(6): 846-861.
Srinivas AN, Suresh D, Santhekadur PK, et al. Extracellular vesicles as inflammatory drivers in NAFLD[J]. Front Immunol, 2020, 11: 627424.
Miao H, Ouyang H, Guo Q, et al. Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism[J]. J Nutr Biochem, 2022, 106: 109020.
Zhou JE,Sun L, Liu L, et al. Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis[J]. J Control Release, 2022, 343: 175-186.
Eguchi A, Feldstein AE. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases[J]. Liver Res, 2018, 2(1): 30-34.
Park SH, Lee EK, Yim J, et al. Exosomes: nomenclature, isolation, and biological roles in liver diseases[J].Biomol Ther (Seoul), 2023, 31: 253-263.
Castaño C, Novials A, Párrizas M. Exosomes from short-term high-fat or high-sucrose fed mice induce hepatic steatosis through different pathways[J]. Cells, 2022, 12(1): 169.
Lee J, Jeong I, Kim OK. Liver-derived exosomes induce inflammation and lipogenesis in mice fed high-energy diets[J]. Nutrients, 2022, 14(23): 5124.
Hughes A, Dahmus J, Rivas G, et al. Exercise training reverses gut dysbiosis in patients with biopsy-proven nonalcoholic steatohepatitis: a proof of concept study[J]. Clin Gastroenterol Hepatol, 2021, 19(8): 1723-1725.
Chandrashekaran V, Seth RK, Dattaroy D, et al. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J]. Redox Biol, 2017, 13: 8-19.
Zhang BB, Zhao JN, Jiang MJ, et al. The potential role of gut microbial-derived exosomes in metabolic-associated fatty liver disease: implications for treatment[J]. Front Immunol, 2022, 13: 893617.
Chen P, Chen FC, Lei JX, et al. Gut microbial metabolite urolithin B attenuates intestinal immunity function in vivo in aging mice and in vitro in HT29 cells by regulating oxidative stress and inflammatory signalling[J]. Food Funct, 2021, 12(23): 11938-11955.
Gaskell H, Ge XD, Desert R, et al. Ablation of Hmgb1 in intestinal epithelial cells causes intestinal lipid accumulation and reduces NASH in mice[J]. Hepatol Commun, 2020, 4(1): 92-108.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies